Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Therapeutic area

Immune system disorders – page 24

  • 1 664 clinical trials
  • 562 recruiting
  • 293 conditions
  • 29 countries

Conditions in this area

293 conditions with trials, the busiest first

Colitis ulcerative120Crohn's disease94Asthma89Dermatitis atopic89HIV infection78Rheumatoid arthritis75Systemic lupus erythematosus63Multiple sclerosis59Psoriasis54Psoriatic arthropathy46Myasthenia gravis44Type 1 diabetes mellitus41Systemic scleroderma40Conjunctivitis allergic34Idiopathic pulmonary fibrosis34Sjogren's syndrome31Cardiac amyloidosis29Interstitial lung disease29Immune thrombocytopenia27Endocrine ophthalmopathy26IgA nephropathy24Vitiligo24Hereditary angioedema22Axial spondyloarthritis21+269

Clinical trials in Immune system disorders

1 664 trials across Europe, recruiting first

Type of trial
Recruitment status
Quick filters

1 664 clinical trials

Systemic scleroderma+2

Recruiting

Study on the Safety of CNTY-101 and Aldesleukin for Patients with Active Autoimmune Diseases: Lupus, Scleroderma, and Myositis

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Aldesleukin
  • Sponsor:Universitaetsklinikum Erlangen AöR

Chronic inflammatory demyelinating polyradiculoneuropathy

Recruiting

Study on Long-term Safety and Efficacy of Riliprubart for Patients with Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

InvestigationalNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Riliprubart
  • Sponsor:Sanofi-Aventis Recherche & Developpement

HIV infection+1

Recruiting

Study on Colchicine to Reduce Heart Artery Inflammation in HIV Patients Over 50 with High Cardiovascular Risk

Registered drug
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Colchicine
  • Sponsor:Fundacion Para La Investigacion Biomedica Del Hospital Universitario La Paz

Asthma

Recruiting

Study on Tozorakimab for Adults with Uncontrolled Asthma Using Medium-to-High Dose Inhaled Corticosteroids

Registered drug
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Salbutamol Sulfate
  • Sponsor:AstraZeneca AB

Crohn's disease

Recruiting

Study on the Effectiveness and Safety of RO7790121 for Patients with Moderate to Severe Crohn's Disease

Investigational
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:RO7790121
  • Sponsor:F. Hoffmann-La Roche AG

Systemic scleroderma

Recruiting

Study on the Effectiveness and Safety of Efgartigimod PH20 SC for Adults with Systemic Sclerosis

Registered drug
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Efgartigimod Alfa
  • Sponsor:Argenx

Alveolar proteinosis

Recruiting

Study on Inhaled Molgramostim for Children with Autoimmune Pulmonary Alveolar Proteinosis

InvestigationalNo placebo
Countries:GermanyGermany
  • Participants:0–17 years
  • Substances:Molgramostim
  • Sponsor:Savara ApS

Wiskott-Aldrich syndrome

Recruiting

Long-term Safety and Efficacy Study of Etuvetidigene Autotemcel for Patients with Wiskott-Aldrich Syndrome

InvestigationalNo placebo
Countries:ItalyItaly
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Etuvetidigene Autotemcel
  • Sponsor:Fondazione Telethon Ets

Rheumatoid arthritis

Recruiting

Study on Rituximab for Patients with Rheumatoid Arthritis: Comparing 200 mg and 1g Doses for Maintenance Treatment

Registered drug
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Rituximab
  • Sponsor:Les Hopitaux Universitaires De Strasbourg

Colitis ulcerative+1

Recruiting

Study on Vedolizumab and Ustekinumab for Patients with Crohn's Disease and Ulcerative Colitis

Registered drugNo placebo
Countries:DenmarkDenmark
  • Participants:18–64 years · 65+ years
  • Substances:Ustekinumab
  • Sponsor:Odense University Hospital

Granulomatosis with polyangiitis

Recruiting

Study on Obinutuzumab for Patients with Relapsing Granulomatosis with Polyangiitis

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Obinutuzumab
  • Sponsor:Assistance Publique Hopitaux De Paris

Myasthenia gravis

Recruiting

Study of Gefurulimab for Children and Teens with Generalized Myasthenia Gravis

InvestigationalNo placebo
Countries:PolandPoland
  • Participants:0–17 years
  • Substances:Gefurulimab
  • Sponsor:Alexion Pharmaceuticals Inc.

Substances studied in this area

The therapies tested most often in Immune system disorders trials.

Sodium Chloride61 clinical trialsRituximab50 clinical trialsPrednisone47 clinical trialsAdalimumab40 clinical trialsEmtricitabine40 clinical trialsTenofovir Alafenamide38 clinical trialsTocilizumab38 clinical trialsMethotrexate37 clinical trialsPrednisolone35 clinical trials
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.